NCT05882214

Brief Summary

The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink. The main questions it aims to answer are:

  1. 1.if NMN administration could accelerate alcohol metabolism and alleviate hangover symptom;
  2. 2.if NMN administration could alleviate alcohol-induced liver injury and hepatic steatosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

May 31, 2023

Completed
11 months until next milestone

Study Start

First participant enrolled

May 1, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 18, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 6, 2025

Completed
Last Updated

April 10, 2025

Status Verified

April 1, 2025

Enrollment Period

10 months

First QC Date

March 16, 2023

Last Update Submit

April 7, 2025

Conditions

Keywords

β-nicotinamide mononucleotideAcute alcohol intakeNutritional supplementationLiver

Outcome Measures

Primary Outcomes (7)

  • Ethanol concentration

    Ethanol concentration change in mg/dL of each set

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • Acetaldehyde concentration

    Acetaldehyde concentration change in mg/dL of each set

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • Hepatic fibrosis change

    Research blood hepatic fibrosis include:Hyaluronicacid in ng/mL;Laminin in ng/mL;type Ⅲ in ng/mL;precollagen in ng/mL;type Ⅳ collagen in ng/mL;Fibronect in ng/mL

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • hepatic function change

    Research blood hepatic function include:TBIL in μmol/L;Direct bilirubin in μmol/L;Indirect bilirubin in μmol/L;Total bile acid in μmol/L

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • hepatic injury change

    Research blood hepatic injury include:Alanine Aminotransferase in U/L;Aspartate Aminotransferase in U/L;Gamma-Glutamyltransferase in U/L;Alpha-Fucosidase in U/L;Alkaline Phosphatase in U/L;cholinesterase in U/L;Lactate Dehydrogenase Enzyme in U/L

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • Lipid metabolism change

    Research blood Fat metabolism include:Triglycerides in mmol/L;HDL-Cholesterol in mmol/L;LDL--Cholesterol in mmol/L;Apolipoprotein A in mmol/L;Apolipoprotein B in mmol/L;Lipoprotein(a) in mmol/L

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • hangover cognition assessment tools after drinking

    The survey tool consisted of many questions addressing cognition headache, nausea,vomiting,fatigue,concentration,thirst or dehydration,light sensitivity,sleeping difficulty,excessive sweating,anxiety,feelings of depression,trembling or shaking,dizziness,stomachache,and memory loss after drinking

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

Secondary Outcomes (4)

  • Laboratory markers of inflammation

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • nicotinamide adenine dinucleotide metabolism change

    day1-2 and day 8-9 of each 30minutes and 1hour and 2 hours and 3 hours and 4 hours and 5 hours and 6 hours and 12 hours and 24 hours

  • Fecal metabolites

    day1-2 and day 8-9 of each set

  • Metabolomics profiling

    day1-2 and day 8-9 of each set

Study Arms (2)

maltodextrin group

PLACEBO COMPARATOR

4 capsule with 1000mg ''maltodextrin''

Dietary Supplement: Maltodextrin

β-nicotinamide mononucleotide group

EXPERIMENTAL

4 capsule with 1000mg ''β-nicotinamide mononucleotide''

Dietary Supplement: β-nicotinamide Mononucleotide

Interventions

After an 8-hour overnight fast, the participants ingested β-nicotinamide Mononucleotide capsules with a single morning dose of 1000mg. The purity of β-nicotinamide Mononucleotide capsules was no less than 97% according to high-performance liquid chromatography analysis.

Also known as: NMN
β-nicotinamide mononucleotide group
MaltodextrinDIETARY_SUPPLEMENT

After an 8-hour overnight fast, the participants ingested maltodextrin capsules with a single morning dose of 1000mg.

maltodextrin group

Eligibility Criteria

Age18 Years - 30 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • a. Sign informed consent

You may not qualify if:

  • Neurological disorders
  • Alcohol allergy
  • Alcohol addiction
  • Gastrointestinal diseases
  • Liver, kidney, cardiovascular or systemic diseases
  • Antibiotics were administered within 2 weeks prior to the trial
  • Participants who ate a vegetarian diet
  • Unable to use a smartphone or computer with Internet access
  • Participate in another intervention study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhejiang Chinese Medical University

Hangzhou, Zhejiang, 310053, China

Location

Related Publications (5)

  • Mammen RR, Natinga Mulakal J, Mohanan R, Maliakel B, Illathu Madhavamenon K. Clove Bud Polyphenols Alleviate Alterations in Inflammation and Oxidative Stress Markers Associated with Binge Drinking: A Randomized Double-Blinded Placebo-Controlled Crossover Study. J Med Food. 2018 Nov;21(11):1188-1196. doi: 10.1089/jmf.2017.4177. Epub 2018 Sep 20.

    PMID: 30234415BACKGROUND
  • Weissenborn R, Duka T. Acute alcohol effects on cognitive function in social drinkers: their relationship to drinking habits. Psychopharmacology (Berl). 2003 Jan;165(3):306-12. doi: 10.1007/s00213-002-1281-1. Epub 2002 Nov 19.

    PMID: 12439627BACKGROUND
  • Kim H, Kim YJ, Jeong HY, Kim JY, Choi EK, Chae SW, Kwon O. A standardized extract of the fruit of Hovenia dulcis alleviated alcohol-induced hangover in healthy subjects with heterozygous ALDH2: A randomized, controlled, crossover trial. J Ethnopharmacol. 2017 Sep 14;209:167-174. doi: 10.1016/j.jep.2017.07.028. Epub 2017 Jul 24.

    PMID: 28750942BACKGROUND
  • Lee MH, Kwak JH, Jeon G, Lee JW, Seo JH, Lee HS, Lee JH. Red ginseng relieves the effects of alcohol consumption and hangover symptoms in healthy men: a randomized crossover study. Food Funct. 2014 Mar;5(3):528-34. doi: 10.1039/c3fo60481k.

    PMID: 24458173BACKGROUND
  • Torp N, Israelsen M, Nielsen MJ, Astrand CP, Juhl P, Johansen S, Hansen CD, Madsen B, Villesen IF, Leeming DJ, Thiele M, Hansen T, Karsdal M, Krag A. Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO-C3). Liver Int. 2022 Jan;42(1):92-101. doi: 10.1111/liv.15120. Epub 2021 Dec 10.

    PMID: 34845832BACKGROUND

MeSH Terms

Conditions

Binge DrinkingFatty Liver

Interventions

maltodextrin

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersAlcohol DrinkingDrinking BehaviorBehaviorMental DisordersLiver DiseasesDigestive System Diseases

Study Officials

  • Jiaomei Li

    Zhejiang Chinese Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
CROSSOVER
Model Details: Intervention method using β-nicotinamide mononucleotide
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 16, 2023

First Posted

May 31, 2023

Study Start

May 1, 2024

Primary Completion

February 18, 2025

Study Completion

April 6, 2025

Last Updated

April 10, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Protect volunteers' personal health data and personal privacy

Locations